<DOC>
	<DOCNO>NCT00357162</DOCNO>
	<brief_summary>This phase II trial study well belinostat work treat patient myelodysplastic syndrome . Belinostat may stop growth cancer cell block enzymes need cell growth block blood flow cancer .</brief_summary>
	<brief_title>Belinostat Treating Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : I . Establish efficacy safety PXD101 ( belinostat ) patient myelodysplastic syndrome progress ineligible azacitidine treatment . II . Assess biological activity PXD101 patient via assay histone acetylation , gene expression profiling , DNA methylation . OUTLINE : This multicenter study . Patients receive belinostat intravenously ( IV ) 30 minute day 1-5 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients achieve complete response , partial response , hematologic improvement 4 course receive 4 additional course therapy . After completion study treatment , patient follow every 3-6 month 3 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Histologically confirm myelodysplastic syndrome ( MDS ) De novo secondary MDS Patients &lt; 5 % bone marrow blast must meet ≥ 1 follow criterion : Symptomatic anemia either hemoglobin &lt; 10.0 g/dL require RBC transfusion within past 3 month Thrombocytopenia ≥ 2 platelet count &lt; 50,000/mm³ significant hemorrhage require platelet transfusion Neutropenia ≥ 2 absolute neutrophil count &lt; 1,000/mm³ No acute myeloid leukemia ( ≥ 20 % bone marrow blast ) ECOG performance status 02 Life expectancy &gt; 12 week Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 2 time ULN Creatinine ≤ 2.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction attribute compound similar chemical biologic composition PXD101 No HIV positivity QTc interval ≤ 500 msec No long QT syndrome No significant cardiovascular disease , include follow : Unstable angina pectoris Uncontrolled hypertension Congestive heart failure relate primary cardiac disease Condition require antiarrhythmic therapy Ischemic severe valvular heart disease Myocardial infarction within past 6 month No uncontrolled serious medical condition ( e.g. , cardiac arrhythmia diabetes ) Recovered prior therapy No 2 prior therapy MDS Prior hematopoietic growth factor , androgen , supportive care agent allow consider prior therapy total No prior allogeneic stem cell transplantation More 4 week since prior radiotherapy chemotherapy ( 6 week nitrosoureas mitomycin C ) No prior histone deacetylase ( HDAC ) inhibitor treatment MDS More 2 week since prior valproic acid HDAC inhibitors No concurrent investigational agent No concurrent medication may cause torsades depointes , include follow : Disopyramide Dofetilide Ibutilide Procainamide Quinidine Sotalol Bepridil Methadone Amiodarone hydrochloride Arsenic trioxide Cisapride Calciumchannel blocker ( e.g. , lidoflazine ) Antiinfective agent ( i.e. , clarithromycin , erythromycin , halofantrine , pentamidine , sparfloxacin ) Domperidone droperidol Antipsychotic agent ( i.e. , chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>